FDA Inspection 1195728 — Embolx, Inc.
The FDA completed an inspection of Embolx, Inc. on Jan 19, 2023 in Sunnyvale, CA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 6 citations were issued during this inspection. Product area: Devices.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Jan 19, 2023
- Fiscal Year
- 2023
- Product Type
- Devices
- Project Area
- Compliance: Devices
- Location
- Sunnyvale, CA (United States)
Citations
| ID | CFR | Description |
|---|---|---|
| 2328 | 21 CFR 820.22 | Quality audits - auditor independence |
| 3375 | 21 CFR 820.198(e) | Records of complaint investigation |
| 3426 | 21 CFR 820.50(a)(1) | Documented evaluation |
| 3696 | 21 CFR 820.100(b) | Documentation |
| 4060 | 21 CFR 820.20(b)(3)(i) | Management representative implementing the quality system |
| 631 | 21 CFR 803.17(a)(1) | Lack of System for Event Evaluations |
Need the full FDA record for Embolx, Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.